Boston, MA, United States of America

Nathanael Schiander Gray

USPTO Granted Patents = 173 


 

Average Co-Inventor Count = 4.2

ph-index = 20

Forward Citations = 1,243(Granted Patents)

Forward Citations (Not Self Cited) = 726(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • La Jolla, CA (US) (2007)
  • San Diego, CA (US) (2005 - 2011)
  • Jamaica Plain, MA (US) (2023)
  • Boston, MA (US) (2008 - 2024)
  • Stanford, CA (US) (2022 - 2024)
  • Boton, MA (US) (2024)

Company Filing History:

goldMedal140 out of 1,210 
 
Dana-Farber-Cancer Institute Inc.
 patents
silverMedal26 out of 151 
 
Irm LLC
 patents
bronzeMedal10 out of 1,187 
 
The Scripps Research Institute
 patents
48 out of 2,893 
 
The General Hospital Corporation
 patents
56 out of 444 
 
The Broad Institute, Inc.
 patents
64 out of 3,923 
 
Novartis Ag
 patents
74 out of 2,968 
 
Harvard College
 patents
83 out of 315 
 
Whitehead Institute For Biomedical Research
 patents
93 out of 2,885 
 
Cornell University
 patents
102 out of 35 
 
University Court Of The University Of Dundee
 patents
112 out of 1,327 
 
Yale University
 patents
122 out of 9 
 
Voronoi Inc.
 patents
131 out of 376 
 
University Of Miami
 patents
141 out of 517 
 
Beth Israel Deaconess Medical Center, Inc.
 patents
151 out of 1 
 
Gatekeeper Pharmaceuticals, Inc.
 patent
161 out of 24 
 
Syros Pharmaceuticals, Inc.
 patents
171 out of 1 
 
Irm LLC (a Delaware Limited Liability Corporation)
 patent
181 out of 1 
 
Irm Llc, a Delware Limited Corporation
 patent
191 out of 5 
 
Fondazione Centro San Raffaele
 patents
201 out of 1,038 
 
Children's Medical Center Corporation
 patents
211 out of 832,880 
Other
 patents
where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Cdk2 Degraders
Egfr Inhibitors
Bruton's Tyrosine Kinase
Cyclin-Dependent Kinase Inhibitors
Wee1 Kinase Degraders
Immunomodulatory Compounds
Alk Inhibitors
Lrrk2 Inhibitors
Crbn Modulators
Pluripotency Induction
Hematologic Malignancies
Malt1 Inhibitors
173 patents (USPTO):Explore Patents

Title: Nathanael Schiander Gray: Innovator and Patent Achievements

Introduction:

Nathanael Schiander Gray, a talented innovator based in Boston, MA, has made significant contributions to the field of biomedical research. Gray's exceptional work in developing groundbreaking technologies and novel compounds has garnered him numerous accolades and awards in recognition of his innovative achievements. In this article, we delve into Gray's latest patents, highlight key milestones in his career, explore his collaborations, and celebrate his remarkable contributions to the field.

Latest Patents:

1. Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use: Gray's pioneering work introduced bifunctional compounds that induce protein degradation of Bruton's tyrosine kinase (BTK). These compounds have the potential to treat disorders modulated by BTK, opening new avenues for therapeutic interventions.

2. Bicyclic urea kinase inhibitors and uses thereof: Gray's research resulted in the development of compounds capable of binding protein kinases, such as SIK (Salt-Inducible Kinases), and potentially modulating their activity. These compounds have shown promise in treating various diseases, ranging from proliferative and musculoskeletal diseases to neurological and metabolic disorders.

Career Highlights:

Nathanael Schiander Gray's career is studded with impressive accomplishments. He has amassed a remarkable 139 patents, amplifying his impact within the field of biomedical research. Gray's unparalleled contributions have earned him prestigious awards, including the Inventor of the Year Award and the Technology Innovator Award, further solidifying his status as a distinguished innovator.

Collaborations:

Gray's collaborative efforts have played a pivotal role in his success. He has worked closely with esteemed institutions and organizations, including Dana-Farber Cancer Institute Inc., a renowned center for cancer research and treatment. Additionally, Gray has collaborated with Irm LLC, an influential scientific research organization, expanding his network and fostering breakthrough innovations.

Some notable collaborators include Hwan Geun Choi and Tinghu Zhang, who have contributed their expertise to Gray's research endeavors. These collaborations have amplified Gray's impact and facilitated the development of innovative solutions to pressing biomedical challenges.

Conclusion:

Nathanael Schiander Gray's unparalleled contributions to the field of biomedical research have established him as a remarkable innovator. Through his inventive work and countless patents, Gray has revolutionized the understanding and treatment of various diseases. His collaborations with prestigious institutions and brilliant colleagues have further accelerated the pace of innovation. Gray's continued dedication to pushing the boundaries of biomedical research makes him an exemplary figure in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…